A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Deuruxolitinib (Primary)
- Indications Alopecia areata
- Focus Adverse reactions; Therapeutic Use
- Sponsors Concert Pharmaceuticals
- 01 Aug 2024 Planned End Date changed from 1 Feb 2025 to 1 May 2025.
- 01 Aug 2024 Planned primary completion date changed from 1 Jan 2025 to 1 May 2025.
- 02 Jul 2024 Status changed from recruiting to active, no longer recruiting.